康辰药业(603590.SH)：KC1086项目获得FDA批准开展临床试验

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received a Clinical Study Continuation Notification from the U.S. Food and Drug Administration (FDA), allowing the clinical trial application for KC1086 to proceed [1] Group 1: Company Developments - The company has developed KC1086, a small molecule inhibitor with a novel structure, targeting Lysine Acetyltransferase 6 (KAT6) [1] - KC1086 is intended for the treatment of advanced recurrent or metastatic solid tumors [1]